Business Wire · RHHBF · October 25, 2026

Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer

Get the app for more

Explore stock news, insights and company research.